PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

mTOR is an important therapeutic target in many types of cancers. In melanoma, the mTOR nonsynonymous mutation rate is up to 10.4%. However, mTOR inhibitors have shown limited effects in clinical trials of melanoma. Because mTOR mutations are distributed, not selecting patients with specific mTOR mu...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Biol Ther
Main Authors: Wu, Xiaowen, Yu, Jiayi, Yan, Junya, Dai, Jie, Si, Lu, Chi, Zhihong, Sheng, Xinan, Cui, Chuanliang, Ma, Meng, Tang, Huan, Xu, Tianxiao, Yu, Huan, Kong, Yan, Guo, Jun
格式: Artigo
語言:Inglês
出版: Taylor & Francis 2018
主題:
Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989792/
https://ncbi.nlm.nih.gov/pubmed/29708815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1435221
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍